BEYOND AIR INC. - COMMON STOCK

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

24 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

21 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

15 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

09 Apr 2025 15:05:00 By Nasdaq GlobeNewswire

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders

01 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

31 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

24 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

11 Mar 2025 06:30:00 By Nasdaq GlobeNewswire

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

06 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

10 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

05 Feb 2025 08:29:17 By Nasdaq GlobeNewswire

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

27 Jan 2025 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

24 Jan 2025 08:15:00 By Nasdaq GlobeNewswire

Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

03 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

02 Dec 2024 06:30:00 By Nasdaq GlobeNewswire

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

26 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

14 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

11 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

11 Nov 2024 06:00:00 By Nasdaq GlobeNewswire